The partnership will advance the making and distribution of electrocardiogram AI algorithms to identify and treat patients with cardiac disease
Novartis headquarters in Basel. (Credit: Silesia711/ Wikipedia)
Health technology company Anumana has entered into a multi-year strategic collaboration with Novartis Pharmaceuticals to detect heart disease leveraging a series of artificial intelligence (AI)-powered software solutions.
The partnership will advance the making and distribution of electrocardiogram (ECG) AI algorithms to assist doctors in quickly identifying and treating patients with life-threatening cardiac illnesses.
It will also aid Anumana’s initiatives to put AI-enabled diagnostic tools in place that can identify signals from ECGs that humans are unable to interpret.
The collaboration’s initial area of attention will be cardiovascular disorders.
Anumana will implement new solutions that use AI to analyse an ECG, a widely accessible, painless test that records the heart’s electrical signals, in collaboration with its partners from Mayo Clinic.
This analysis will help identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can result in heart failure.
Atherosclerotic cardiovascular disease, which can cause a heart attack or stroke, will also be screened for by the AI.
Additionally, a digital, evidence-based point-of-care solution will be created to assist in optimising medical interventions in an effort to reduce the risk of possibly needless hospitalizations and cardiovascular deaths.
Anumana CEO Murali Aravamudan said: “Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms.
“Bringing together premier global organisations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”
In recent research, single-lead ECGs in smartwatches were utilised to diagnose left ventricular dysfunction using a modified version of Anumana’s 12-lead ECG algorithm.
These algorithms have been validated by more than 30 peer-reviewed papers and are licensed to Anumana for the creation of healthcare solutions.
The FDA has not yet approved the ECG AI algorithm for use in commercial healthcare settings.